Meeting NewsVideo

VIDEO: Ipilimumab-nivolumab emerges as new standard for metastatic renal cell carcinoma

MIAMI  Combination use of ipilimumab plus nivolumab can be considered the standard of care for the frontline treatment of patients with metastatic renal cell carcinoma, Brian I. Rini, MD, from the department of solid tumor oncology at Cleveland Clinic Taussig Cancer Center, said at the International Kidney Cancer Symposium.

In this video, Rini, also a HemOnc Today Editorial Board Member, discussed results from the randomized, open-label phase 3 Checkmate-214 study.

The trial evaluated the safety and efficacy of nivolumab (Opdivo, Bristol-Myers Squibb) in combination with ipilimumab (Yervoy, Bristol-Myers Squibb) compared with sunitinib (Sutent, Pfizer) in 1,096 adults with measurable clear-cell metastatic renal cell carcinoma and a Karnofsky performance score of 70 or greater.

Of note, more patients who received the combination arm achieved complete response (9% vs. 1%) or partial response (32% vs. 25%).

“In my mind, this is really an emerging standard of care in the frontline treatment of patients,” Rini said. by Kristie L. Kahl

 

Reference:

Rini B. IO is the new standard of care for all mRCC patients. Presented at: International Kidney Cancer Symposium; Nov. 3-4, 2017; Miami.

 

Disclosure: Rini reports consultant roles with Accelion, Novartis and Pfizer; and research funding from Bristol-Myers Squibb, Immatics, Peleton and Pfizer; and expenses from Pfizer.

MIAMI  Combination use of ipilimumab plus nivolumab can be considered the standard of care for the frontline treatment of patients with metastatic renal cell carcinoma, Brian I. Rini, MD, from the department of solid tumor oncology at Cleveland Clinic Taussig Cancer Center, said at the International Kidney Cancer Symposium.

In this video, Rini, also a HemOnc Today Editorial Board Member, discussed results from the randomized, open-label phase 3 Checkmate-214 study.

The trial evaluated the safety and efficacy of nivolumab (Opdivo, Bristol-Myers Squibb) in combination with ipilimumab (Yervoy, Bristol-Myers Squibb) compared with sunitinib (Sutent, Pfizer) in 1,096 adults with measurable clear-cell metastatic renal cell carcinoma and a Karnofsky performance score of 70 or greater.

Of note, more patients who received the combination arm achieved complete response (9% vs. 1%) or partial response (32% vs. 25%).

“In my mind, this is really an emerging standard of care in the frontline treatment of patients,” Rini said. by Kristie L. Kahl

 

Reference:

Rini B. IO is the new standard of care for all mRCC patients. Presented at: International Kidney Cancer Symposium; Nov. 3-4, 2017; Miami.

 

Disclosure: Rini reports consultant roles with Accelion, Novartis and Pfizer; and research funding from Bristol-Myers Squibb, Immatics, Peleton and Pfizer; and expenses from Pfizer.

    See more from International Kidney Cancer Symposium